Stock listing
OTC:EFTR eFFECTOR Therapeutics Inc Stock
Follow eFFECTOR Therapeutics Inc into a list and get an email when it puts out news.
Share price · OTC:EFTR
$0.0002 USD 0.0000 (0.0%)
Close on Nov 19, 2026
- Day range
- $0.0002 – $0.0002 USDNov 19, 2026
- 52-week range
- $0.0002 – $0.0100 USDLowest and highest trades, Nov 20, 2025 – Nov 19, 2026
- Traded on an average day
- $1 USDMedian day 0 shares · 42 days with no trades · last 3 months, Aug 19, 2026 – Nov 19, 2026

Daily closes
Last 3 months, Aug 19, 2026 – Nov 19, 2026 · OTC:EFTR · USD, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| $0.0002 | 0.0000 | 0.0% | $0.0002 | $0.0002 | $0.0002 | 0 | |
| $0.0002 | 0.0000 | 0.0% | $0.0002 | $0.0002 | $0.0002 | 400 | |
| $0.0002 | 0.0000 | 0.0% | $0.0002 | $0.0002 | $0.0002 | 3,500 | |
| $0.0002 | 0.0000 | 0.0% | $0.0002 | $0.0002 | $0.0002 | 712 | |
| $0.0002 | 0.0000 | 0.0% | $0.0002 | $0.0002 | $0.0002 | 0 | |
| $0.0002 | 0.0000 | 0.0% | $0.0002 | $0.0002 | $0.0002 | 0 | |
| $0.0002 | 0.0000 | 0.0% | $0.0002 | $0.0002 | $0.0002 | 0 | |
| $0.0002 | 0.0000 | 0.0% | $0.0002 | $0.0002 | $0.0002 | 0 | |
| $0.0002 | 0.0000 | 0.0% | $0.0002 | $0.0002 | $0.0002 | 0 | |
| $0.0002 | 0.0000 | 0.0% | $0.0002 | $0.0002 | $0.0002 | 300 | |
| $0.0002 | 0.0000 | 0.0% | $0.0002 | $0.0002 | $0.0002 | 0 | |
| $0.0002 | 0.0000 | 0.0% | $0.0002 | $0.0002 | $0.0002 | 119 | |
| $0.0002 | 0.0000 | 0.0% | $0.0002 | $0.0002 | $0.0002 | 0 | |
| $0.0002 | 0.0000 | 0.0% | $0.0002 | $0.0002 | $0.0002 | 0 | |
| $0.0002 | 0.0000 | 0.0% | $0.0002 | $0.0002 | $0.0002 | 0 | |
| $0.0002 | 0.0000 | 0.0% | $0.0002 | $0.0002 | $0.0002 | 0 | |
| $0.0002 | 0.0000 | 0.0% | $0.0002 | $0.0002 | $0.0002 | 0 | |
| $0.0002 | 0.0000 | 0.0% | $0.0002 | $0.0002 | $0.0002 | 0 | |
| $0.0002 | 0.0000 | 0.0% | $0.0002 | $0.0002 | $0.0002 | 0 | |
| $0.0002 | 0.0000 | 0.0% | $0.0002 | $0.0002 | $0.0002 | 0 | |
| $0.0002 | 0.0000 | 0.0% | $0.0002 | $0.0002 | $0.0002 | 0 | |
| $0.0002 | 0.0000 | 0.0% | $0.0008 | $0.0008 | $0.0002 | 1,700 | |
| $0.0002 | 0.0000 | 0.0% | $0.0002 | $0.0002 | $0.0002 | 0 | |
| $0.0002 | 0.0000 | 0.0% | $0.0002 | $0.0008 | $0.0002 | 5,903 | |
| $0.0002 | 0.0000 | 0.0% | $0.0002 | $0.0002 | $0.0002 | 0 | |
| $0.0002 | 0.0000 | 0.0% | $0.0002 | $0.0002 | $0.0002 | 0 | |
| $0.0002 | 0.0000 | 0.0% | $0.0002 | $0.0002 | $0.0002 | 0 | |
| $0.0002 | 0.0000 | 0.0% | $0.0002 | $0.0002 | $0.0002 | 817 | |
| $0.0002 | 0.0000 | 0.0% | $0.0002 | $0.0002 | $0.0002 | 0 | |
| $0.0002 | 0.0000 | 0.0% | $0.0002 | $0.0002 | $0.0002 | 0 | |
| $0.0002 | 0.0000 | 0.0% | $0.0002 | $0.0002 | $0.0002 | 0 | |
| $0.0002 | 0.0000 | 0.0% | $0.0002 | $0.0002 | $0.0002 | 0 | |
| $0.0002 | 0.0000 | 0.0% | $0.0002 | $0.0002 | $0.0002 | 0 | |
| $0.0002 | 0.0000 | 0.0% | $0.0002 | $0.0002 | $0.0002 | 0 | |
| $0.0002 | -0.0006 | -75.0% | $0.0002 | $0.0002 | $0.0002 | 100 | |
| $0.0008 | 0.0000 | 0.0% | $0.0008 | $0.0008 | $0.0008 | 0 | |
| $0.0008 | 0.0000 | 0.0% | $0.0008 | $0.0008 | $0.0008 | 0 | |
| $0.0008 | 0.0000 | 0.0% | $0.0008 | $0.0008 | $0.0008 | 0 | |
| $0.0008 | 0.0000 | 0.0% | $0.0008 | $0.0008 | $0.0008 | 0 | |
| $0.0008 | 0.0000 | 0.0% | $0.0008 | $0.0008 | $0.0008 | 0 | |
| $0.0008 | 0.0000 | 0.0% | $0.0008 | $0.0008 | $0.0008 | 0 | |
| $0.0008 | 0.0000 | 0.0% | $0.0002 | $0.0008 | $0.0002 | 331 | |
| $0.0008 | 0.0000 | 0.0% | $0.0008 | $0.0008 | $0.0008 | 0 | |
| $0.0008 | 0.0000 | 0.0% | $0.0008 | $0.0008 | $0.0008 | 0 | |
| $0.0008 | 0.0000 | 0.0% | $0.0008 | $0.0008 | $0.0008 | 500 | |
| $0.0008 | +0.0005 | +166.7% | $0.0002 | $0.0008 | $0.0002 | 378 | |
| $0.0003 | 0.0000 | 0.0% | $0.0003 | $0.0003 | $0.0003 | 0 | |
| $0.0003 | 0.0000 | 0.0% | $0.0003 | $0.0003 | $0.0003 | 0 | |
| $0.0003 | 0.0000 | 0.0% | $0.0003 | $0.0003 | $0.0003 | 0 | |
| $0.0003 | 0.0000 | 0.0% | $0.0003 | $0.0003 | $0.0003 | 0 | |
| $0.0003 | 0.0000 | 0.0% | $0.0003 | $0.0003 | $0.0003 | 0 | |
| $0.0003 | 0.0000 | 0.0% | $0.0003 | $0.0003 | $0.0003 | 0 | |
| $0.0003 | -0.0005 | -62.5% | $0.0003 | $0.0003 | $0.0003 | 112,137 | |
| $0.0008 | 0.0000 | 0.0% | $0.0008 | $0.0008 | $0.0008 | 0 | |
| $0.0008 | 0.0000 | 0.0% | $0.0008 | $0.0008 | $0.0008 | 0 |
Splits
1 split · OTC:EFTR · every price before a split is adjusted for it
| Day | Ratio | What |
|---|---|---|
| 1-for-25 | Consolidation |
- Ticker
- OTC:EFTR
- Asset type
- Stock
- Exchange
- OTC
- Currency
- USD
eFFECTOR Therapeutics Inc on 6ix
- Decks
- 5 decks · latest Jan 5, 2023
Valuation
price Nov 19, 2026
- Enterprise value
- No market cap
- P/E
- No market cap
- EV/sales
- No market cap
- EV/EBITDA
- No market cap
- Price/book
- No market cap
- Gross margin
- No statements on 6ix yet
- Operating margin
- No statements on 6ix yet
- Net margin
- No statements on 6ix yet
- Debt to equity
- No statements on 6ix yet
- Beta vs S&P 500
- 0.01
Events
| Quarter | Results | Share move |
|---|---|---|
| Q1 2024 | May 9, 2024 · After close | −5.1% |
| Q4 2023 | Mar 25, 2024 · After close | −6.2% |
| Q3 2023 | Nov 13, 2023 · After close | +1.1% |
| Q2 2023 | Aug 8, 2023 · After close | −5.8% |
| Q1 2023 | May 9, 2023 · After close | −2.4% |
| Q4 2022 | Mar 8, 2023 · After close | −3.4% |
| Q3 2022 | Nov 7, 2022 · After close | +0.8% |
| Q2 2022 | Aug 9, 2022 · After close | +12.7% |
| Q1 2022 | May 10, 2022 · After close | −6.5% |
| Q4 2021 | Mar 16, 2022 · After close | +6.6% |
All 13 quarters
| Quarter | Results | Share move |
|---|---|---|
| Q3 2021 | Nov 8, 2021 · Before open | +6.2% |
| Q2 2021 | Aug 31, 2021 · Before open | −3.0% |
| Q1 2021 | Jun 3, 2021 · Before open | −0.2% |
Decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Corporate Update (January 2023) | Corporate update | 22 slides | Jan 5, 2023 |
| Corporate Update (January 2022) | Corporate update | 15 slides | Jan 24, 2022 |
| Locust Walk Acquisition — SPAC Merger (June 2021) | SPAC merger | 48 slides | Jun 28, 2021 |
| SPAC Merger (May 2021) | SPAC merger | 37 slides | May 27, 2021 |
| SPAC Merger (May 2021) | SPAC merger | 50 slides | May 27, 2021 |
Financials
Annual, in USD
Income statement
| Line | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|
| Revenue | 0 | 3.55M | 1.43M | 42.0M | |
| Cost of revenue | 111.0K | 53.0K | 24.0K | 160.0K | 307.0K |
| Gross profit | -111.0K | 3.50M | 1.43M | 42.0M | -307.0K |
| Research and development | 22.9M | 23.3M | 20.0M | 21.8M | 23.6M |
| Selling, general and administrative | 10.9M | 12.6M | 13.4M | 4.35M | 4.71M |
| Operating income | -33.8M | -32.4M | -31.9M | 15.8M | -28.6M |
| Depreciation and amortization | 111.0K | 53.0K | 24.0K | 160.0K | 307.0K |
| EBITDA | -33.7M | -32.4M | -31.9M | 16.0M | -28.3M |
| Interest expense | 2.92M | 2.25M | 1.76M | 1.33M | 1.38M |
| Income before tax | -35.8M | -22.7M | 15.8M | 14.6M | -29.7M |
| Income tax | -9.74M | -24.0K | 351.0K | 135.1K | |
| Net income | -35.8M | -12.9M | 15.8M | 14.2M | -29.7M |
| Earnings per share, basic | -16.37 | -7.85 | 9.78 | 23.74 | -539.08 |
Balance sheet
| Line | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|
| Cash and equivalents | 14.9M | 8.71M | 49.7M | 15.2M | 3.43M |
| Short-term investments | 3.50M | 17.6M | 0 | ||
| Receivables | 52.0K | 27.0K | 100.0K | ||
| Inventory | -27.0K | -100.0K | |||
| Current assets | 19.8M | 28.0M | 52.9M | 16.6M | 4.27M |
| Property, plant and equipment | 352.0K | 91.0K | 126.0K | 823.0K | |
| Total assets | 20.5M | 29.1M | 54.1M | 16.7M | 5.09M |
| Accounts payable | 2.33M | 1.49M | 516.0K | 347.0K | 598.0K |
| Current liabilities | 25.8M | 25.1M | 3.98M | 8.78M | 18.9M |
| Long-term debt | 19.9M | 6.95M | |||
| Total debt | 20.5M | 20.3M | 20.0M | 13.0M | 15.2M |
| Total liabilities | 26.3M | 25.2M | 36.8M | 148.9M | 18.9M |
| Shareholders' equity | -5.79M | 3.90M | 17.3M | 979.0K | -13.8M |
| Shares outstanding | 2.19M | 1.65M | 1.62M | 598.6K | 55.2K |
Cash flow
| Line | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|
| Cash from operations | -29.6M | -25.9M | -24.9M | 13.8M | -27.6M |
| Capital spending | -97.0K | -192.0K | -42.0K | -154.0K | -4.00K |
| Free cash flow | -29.6M | -26.1M | -24.9M | 13.7M | -27.6M |
| Cash from investing | 14.5M | -17.9M | 565.0K | -154.0K | 84.0K |
| Cash from financing | 21.2M | 2.77M | 58.8M | -1.89M | 20.2M |
| Share buybacks | 56.0K | -86.0K | |||
| Change in cash | 6.17M | -41.0M | 34.5M | 11.8M | 3.43M |
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|---|
| Caroline M Loewy Other companies: CERo Therapeutics Holdings, Inc. (Director · Oct 5, 2021 – Feb 14, 2024 · Past); Zogenix Inc (Director · Sep 21, 2020 – Mar 7, 2022 · Past); Aptose Biosciences Inc (Director · Dec 21, 2018 – Jan 18, 2022 · Past); PhaseBio Pharmaceuticals Inc (Director · Oct 17, 2018 – May 19, 2023 · Past) | Director · Sep 9, 2023 – Jun 13, 2024 · Past |
| Brian M Gallagher Jr Other companies: Translate Bio Inc (Director · Jun 27, 2018 – Jul 2, 2018 · Past); Rein Therapeutics, Inc. (Director · Jun 28, 2017 – Jul 25, 2017 · Past) | Director · Aug 25, 2021 – Jun 13, 2024 · Past |
| Premal Patel | Chief Medical Officer · Aug 25, 2021 – Jan 20, 2022 · Past |
Log in to ask 6ix AI your own questions about eFFECTOR Therapeutics Inc.